finance News

DUBLIN — The “Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” report has been added to  ResearchAndMarkets.com’s offering. The global multiple myeloma drugs market has experienced substantial growth, achieving a noteworthy US$ 21.0 Billion in 2022. Projections by industry experts indicate continued expansion, with the...
LOUISVILLE, Ky. – Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by Kadmon Pharmaceuticals, LLC to be a specialty pharmacy partner for REZUROCK (belumosudil), a new oral treatment for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure...
SUNNYVALE, Calif. – Rubedo Life Sciences, a drug discovery company developing targeted therapeutics for age-related diseases, today announced a collaboration with Cedars-Sinai Medical Center in Los Angeles, to advance its idiopathic pulmonary fibrosis (IPF) program and establish collaborative studies. As part of the collaboration, Cory Hogaboam, Ph.D., Professor of Medicine...
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced it received approximately USD $2.9 million (SEK 24.2 million) in an upfront payment resulting from the now completed acquisition of Cadent Therapeutics by a third party. Saniona holds an ownership stake of approximately 3% in Cadent Therapeutics...
CAMBRIDGE, Mass. – Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the website for Route 79, The Duchenne Scholarship Program, is officially open and accepting applications. Academic scholarships of up to $5,000 will be awarded to up to 15 individuals chosen by...
LOS ANGELES – Science 37, the industry leader in decentralized clinical trials, announced today a partnership with Xperiome, a global rare disease healthtech company. The partnership further strengthens Science 37’s capabilities to bring research directly to patients, both by easing the patient burden and enabling treating physicians the opportunity to...
LISSES, France – Sebia, a leading provider of clinical protein electrophoresis equipment and reagents for diabetes and oncology detection, today announced the acquisition of specialty diagnostic leader ORGENTEC Diagnostika from Water Street Healthcare Partners, a strategic investor focused exclusively on healthcare, for an undisclosed amount. The transaction is expected to close in the next quarter. The...